In short
This article discusses a clinical trial investigating the use of Blomia tropicalis allergenic extract in skin prick tests for diagnosing mite allergies. The study aims to standardize the biological activity of various mite extracts, including Blomia tropicalis, to improve allergy diagnosis and treatment.
At a glance
- Study Drug
- Blomia tropicalis allergenic extract
- Administration Method
- Solution for skin prick test
- Main Objective
- Standardize biological activity of mite extracts, including Blomia tropicalis
- Primary Endpoint
- Wheal area (mm²) after skin prick test
- Key Inclusion Criteria
- Age 18-65, history of allergy, sensitization to mite allergens
- Key Exclusion Criteria
- Recent mite immunotherapy, severe diseases, pregnancy
- Safety Assessment
- Monitoring of adverse reactions during the study
What is Blomia Tropicalis?
Blomia tropicalis is a type of dust mite that is commonly found in tropical and subtropical regions. It's known to cause allergic reactions in sensitive individuals, similar to other dust mite species.
Blomia Tropicalis Allergenic Extract
The allergenic extract of Blomia tropicalis is a medical product used for diagnosing and potentially treating allergies caused by this specific dust mite. It's officially called "Blomia tropicalis skin-prick test" and comes in the form of a solution.
Medical Use and Purpose
The primary purpose of this allergenic extract is for diagnostic use. It's used in a procedure called a skin prick test, which helps doctors determine if a patient is allergic to Blomia tropicalis. During this test, a small amount of the solution is placed on the skin, and then the skin is lightly pricked. If a person is allergic, a small, raised bump (called a wheal) will appear at the test site.
How is it Administered?
The Blomia tropicalis allergenic extract is administered through a skin prick test. This is typically done on the forearm or back. The maximum concentration used is 10 mg/ml, and the test usually takes only a few minutes to perform.
Who is Eligible for Treatment?
Based on the clinical trial information, individuals who might be eligible for this test include:
- Adults aged 18-65 years
- People with a medical history suggesting allergy
- Individuals with demonstrated sensitivity to allergens, including Blomia tropicalis
- Those who have not received immunotherapy for mite allergies in the past 5 years
It's important to note that a doctor will determine if this test is appropriate for each individual patient.
Who Should Not Use This Treatment?
Several factors may exclude someone from receiving this test. These include:
- Pregnancy or breastfeeding
- Recent use of antihistamines (within 7 days)
- Certain skin conditions affecting the test area
- Use of specific medications that might interfere with the test results
- Certain immune system disorders
- History of severe reactions to previous skin tests
Always inform your healthcare provider about your medical history and any medications you're taking.
Safety and Side Effects
While the skin prick test is generally considered safe, there is always a potential for adverse reactions. The clinical trial is designed to assess the safety and tolerability of the Blomia tropicalis extract. Possible side effects may include local skin reactions or, in rare cases, more severe allergic reactions. Medical professionals performing the test are prepared to handle any potential reactions.
Ongoing Research
The Blomia tropicalis allergenic extract is currently part of a clinical trial. This research aims to standardize the biological activity of various mite allergens, including Blomia tropicalis. The goal is to determine the concentration of the extract that produces a skin reaction equivalent to a standard histamine solution. This standardization will help ensure consistent and reliable allergy testing across different patients and clinics.